Dactinomycin


Catalog No. size PriceQuantity
M6979-2 2mg solid $101
M6979-10 10mg solid $416

Description

Cas:50-76-0

Product Information:

Dactinomycin (also known generically as Actinomycin D) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces. As one of the older chemotherapy drugs, it has been used for many years. Actinomycin D was the first antibiotic shown to have anti-cancer activity. It was first isolated by Selman Waksman and his co-worker H. B. Woodruff in 1940. It was approved by the US FDA on December 10, 1964 and launched by Merck Sharp and Dohme under the trade name Cosmegen.

 

Chemical Formula: C62H86N12O16

 

Exact Mass: 1254.62847

 

Molecular Weight: 1255.42

 

Elemental Analysis: C, 59.32; H, 6.90; N, 13.39; O, 20.39

 

Synonym: 

 

Abbreviation

DACT

ACTD

actinomycin C1

actinomycin D

actinomycin I1

actinomycin IV

actinomycin X 1

Actinomycinthrvalprosarmeval

Dactinomycine

Meractinomycin

US brand names

Cosmegen

Lyovac

 

Chemical Name: 

2-amino-N1,N9-bis((6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1]oxa[4,7,10,13]tetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

 

InChi Key:

RJURFGZVJUQBHK-IIXSONLDSA-N

 

InChi Code:

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

 

Smiles Code:

O=C(N[C@@H]1C(N[C@@H](C(N2[C@]([H])(C(N(CC(N([C@H](C(O[C@@H]1C)=O)C(C)C)C)=O)C)=O)CCC2)=O)C(C)C)=O)C3=C(C(C(C)=C4OC5=C(C(C(N[C@@H]([C@@H](C)O6)C(N[C@H](C(C)C)C(N7CCC[C@@]7([H])C(N(C)CC(N(C)[C@@H](C(C)C)C6=O)=O)=O)=O)=O)=O)=CC=C5C)N=C43)=O)N

 

 

Technical Data:

 

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

 

 

References:

 

  1. Weaver MS, Navid F, Huppmann A, Meany H, Angiolillo A. Vincristine and Dactinomycin in Infantile Myofibromatosis With a Review of Treatment Options. J Pediatr Hematol Oncol. 2014 Nov 11. [Epub ahead of print] PubMed PMID: 25389917.

 

  1. Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2014 Nov 1;32(31):3547-52. doi: 10.1200/JCO.2014.55.6787. Epub 2014 Sep 29. PubMed PMID: 25267746; PubMed Central PMCID: PMC4209105.

 

  1. Raggi D, Giannatempo P, Miceli R, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Marongiu M, Gianni AM, Nicolai N, Salvioni R, Necchi A. Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. Am J Clin Oncol. 2014 Aug 7. [Epub ahead of print] PubMed PMID: 25089532.

 

  1. Wang T, Feng FZ, Xiang Y, Wan XR, Ren T. Combination chemotherapy regimen with floxuridine, dactinomycin, etoposide, and vincristine as primary treatment for gestational trophoblastic neoplasia. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Jun;36(3):300-4. doi: 10.3881/j.issn.1000-503X.2014.03.013. PubMed PMID: 24997824.

 

  1. Han SN, Amant F, Leunen K, Devi UK, Neven P, Vergote I. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2012 Jun;22(5):875-80. doi: 10.1097/IGC.0b013e31824d834d. PubMed PMID: 22635033.

 

Products are for research use only. Not for human use.

 

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed